- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07916103
HA-Coated and Non-HA Threads for Midface Lifting and Nasolabial Fold Correction
Evaluation of Safety and Effectiveness of APTOS Threads - Absorbable Surgical Sutures Excellence Product Line Models for Mid-face Suspension by Mini-Invasive Surgery to Temporarily Fixate the Cheek Sub-dermis in a Repositioned Site for the Treatment of Moderate to Severe Nasolabial Fold.
This randomized study compared absorbable facial lifting threads with and without a hyaluronic acid (HA) coating in 144 adults with moderate-to-severe nasolabial folds, the lines extending from the sides of the nose toward the corners of the mouth. Participants were randomly assigned in a 1:1 ratio to receive either HA-coated or non-HA threads.
Follow-up continued for six months. The main assessments evaluated adverse events through Day 30 and changes in nasolabial fold severity at Day 90. Independent evaluators assessed standardized photographs, and participants rated their aesthetic improvement and satisfaction. Additional assessments examined safety and maintenance of improvement through Day 180
Přehled studie
Postavení
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Batumi, Gruzie, 6000
- "Total Charm Piazza",15 Vakhtang Gorgasali Street
-
Tbilisi, Gruzie, 0109
- "Total Charm LTD", Orbeliani Str #18
-
Tbilisi, Gruzie, 0162
- "Total Charm Vake", 87B Zakaria Paliashvili Street
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male and female subjects, 22+ years of age.
- Subjects who desire cheek lifting to correct age-related wrinkles in the mid-face as recommended by the treating investigator.
- Subject received a rating, in each cheek, by Investigator of at least Grade 3 or Grade 4 for wrinkling of the NLF in the mid-face according to the WSRS.
- If a woman is of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), then she must have a confirmed negative urine pregnancy test result at screening. If treatment is not provided at the screening visit, a negative urine pregnancy test result is required within 7 days before treatment.
- If a woman of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), subject confirms she will utilize at least one form of contraception throughout the duration of the study (6 months).
- Subjects who are able to understand the study requirements, including the obligation not to receive any other facial procedures or treatments affecting mid-face at any time during the study. These include procedures or treatments done at home or with a professional. Facial treatments include lasers, facial massages, and anything beyond common skincare routine.
- Subjects who are willing to participate in the study and to sign a witnessed/informed consent form.
- Subjects who are logistically able to present for all study visits and meet all study requirements.
- Subjects who are willing to complete a 30-day diary.
- Subjects who pass the pinprick and/or cotton swab facial nerve assessment
Exclusion Criteria:
- Abnormal rating in mid-face sensation, with inability to feel a 0.4 G monofilament or a cotton wisp at any site on the mid-face.
- Active acne or prominent acne scars in the treatment area.
- Active inflammatory or infectious conditions.
- Allergy or foreign body sensitivities to plastic biomaterials.
- Known bleeding disorder.
- Breast feeding, pregnant, or not on/willing to use contraception if of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile).
- Known collagen skin disorder.
- Pre-existing facial asymmetry.
- History of any device use on the mid-face in the prior 6 months (laser, Intense Pulsed Light [IPL], radiofrequency (RF), ultrasound, micro needling, micro needle RF, or cool based treatments).
- History of autoimmune or connective tissue disease.
- History of facelift, mid-face lift, lower facelift or neck lift that changes the facial structure and anchor points.
- History of fat transfer to the mid-face.
- History of injectable fillers other than temporary fillers such as HA or Radiesse to the mid-face at any time. Permanent and semi-permanent fillers are not allowed (Poly-L-lactic acids [PLLA], Sculptra).
- History of Kybella in the prior 6 months.
- History of facial trauma in the mid-face.
- History of facial surgical procedures.
- Inability to chew, puff cheek, or smile broadly.
- Metabolism irregularities.
- Receiving immunosuppressive therapy.
- Recent weight loss or intention to lose a significant amount of weight during the study period (2 body mass index [BMI] points).
- Subjects who have undergone cosmetic facial plastic surgery (with the exception of rhinoplasty or upper blepharoplasty) more than 2 years prior to enrollment, tissue grafting, or tissue lifting or augmentation with any permanent or semi-permanent filler.
- Subjects who have had temporary facial dermal filler injections below the orbital rim with HA-based fillers or Radiesse within 18 months, porcine-based collagen fillers within 24 months, or neuromodulator injections to the mid-face or lateral canthal lines, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months of entry in the study or who were planning to undergo any of these procedures at any time during the study.
- Subjects who have very thin skin in the mid-face region, who have a tendency to accumulate fluid in the lower eyelids, or who have large infraorbital fat pads (i.e., significant convexity or projection from the infraorbital fat pads).
- Subjects who have mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIVrelated disease.
- Subjects who are included to list of vulnerable populations (pediatric, pregnant, elderly individuals with visual or hearing impairments, mentally ill subjects).
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: HA-Coated P(LA/CL) Lifting Threads
Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads coated with hyaluronic acid in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence HA, Visage Excellence Soft HA, or Nano Excellence HA threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation. |
The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] and coated with non-animal-derived, non-cross-linked, medium-molecular-weight sodium hyaluronate. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence HA (190 mm), Visage Excellence Soft HA (100 mm), and Nano Excellence HA (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning. |
|
Experimentální: Non-HA-Coated P(LA/CL) Lifting Threads
Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads without hyaluronic acid coating in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence, Visage Excellence Soft, or Nano Excellence threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation. |
The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] without hyaluronic acid coating. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence (190 mm), Visage Excellence Soft (100 mm), and Nano Excellence (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Incidence of device and procedure related serious adverse events by Day 30 (Month 1) after the implantation procedure.
Časové okno: From implantation through Day 30.
|
From implantation through Day 30.
|
|
Reduction in NLF severity at Day 90 (Month 3) after the implantation procedure in comparison with baseline grading, as assessed by blinded evaluators using the Wrinkles Severity Rating Scale (WSRS).
Časové okno: Baseline and Day 90 after implantation
|
Baseline and Day 90 after implantation
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Incidence of all adverse events after implantation of threads throughout the whole study.
Časové okno: through Day 180 [Month 6] after the implantation procedure
|
through Day 180 [Month 6] after the implantation procedure
|
|
Incidence of early recovery symptoms related to the treatment (threads implantation) among adverse events reported by both patients and treating physician(s)
Časové okno: Up to Day 14 after the implantation procedure.
|
Up to Day 14 after the implantation procedure.
|
|
Observed values and change from baseline in WSRS
Časové okno: On Day 30 and Day 180.
|
On Day 30 and Day 180.
|
|
The proportion of subjects with improvement of ≥1 WSRS score at each visit
Časové okno: Days 30, 90, and 180 after implantation.
|
Days 30, 90, and 180 after implantation.
|
|
Mean GAIS value assessed by blinded evaluators with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
Časové okno: On Day 30, Day 90, and Day 180
|
On Day 30, Day 90, and Day 180
|
|
Mean GAIS value assessed by subject with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
Časové okno: Days 30, 90, and 180 after implantation.
|
Days 30, 90, and 180 after implantation.
|
|
Patient satisfaction with the procedure outcome assessed using the mean total Face-QTM Satisfaction with Outcome score.
Časové okno: At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.
|
At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Anna Kadzhaya, MD, Aptos LLC, Tbilisi, Georgia.15 Givi Amilakhvari Street
Publikace a užitečné odkazy
Obecné publikace
- Niu Z, Zhang K, Yao W, Li Y, Jiang W, Zhang Q, Troulis MJ, August M, Chen Y, Han Y. A Meta-Analysis and Systematic Review of the Incidences of Complications Following Facial Thread-Lifting. Aesthetic Plast Surg. 2021 Oct;45(5):2148-2158. doi: 10.1007/s00266-021-02256-w. Epub 2021 Apr 5.
- Day DJ, Littler CM, Swift RW, Gottlieb S. The wrinkle severity rating scale: a validation study. Am J Clin Dermatol. 2004;5(1):49-52. doi: 10.2165/00128071-200405010-00007.
- Ziade G, Daou D, Karam D, Tsintsadze M. The third generation barbed lifting threads: Added value of hyaluronic acid. J Cosmet Dermatol. 2024 Jan;23(1):186-192. doi: 10.1111/jocd.15885. Epub 2023 Jul 19.
- Wong V. The Science of Absorbable Poly(L-Lactide-Co-epsilon-Caprolactone) Threads for Soft Tissue Repositioning of the Face: An Evidence-Based Evaluation of Their Physical Properties and Clinical Application. Clin Cosmet Investig Dermatol. 2021 Jan 13;14:45-54. doi: 10.2147/CCID.S274160. eCollection 2021.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- Excellence - 001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .